<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740047</url>
  </required_header>
  <id_info>
    <org_study_id>20-004757</org_study_id>
    <nct_id>NCT04740047</nct_id>
  </id_info>
  <brief_title>Cios Mobile 3D Spin for Robotic Bronchoscopy</brief_title>
  <official_title>Cios Mobile 3D Spin for Robotic Bronchoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Intuitive</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Siemens Corporation, Corporate Technology</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the clinical utility and early performance of the Cios 3D Mobile Spin in conjunction&#xD;
      with the Ion Endoluminal System, to visualize and facilitate the sampling of pulmonary&#xD;
      nodules between 1-3 cm via the airway.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tool in Lesion</measure>
    <time_frame>At the time of the procedure</time_frame>
    <description>Ability to visualize on 3D imaging the pre-planned target location characterized when displayed distance of catheter tip to nearest edge of the virtual target is ≤ 2cm and is oriented towards the lesion in 3 axes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure-related complications</measure>
    <time_frame>6 months</time_frame>
    <description>Overall incidence of procedure-related complications recorded as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration-related outcomes</measure>
    <time_frame>At the time of the procedure</time_frame>
    <description>Reporting of times related to procedure times including procedure time, navigation time, time to 3D comfirmation, time to tissue acquisitions, anesthia time, and fluoroscopy time and dose.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pulmonary Nodule, Solitary</condition>
  <condition>Pulmonary Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Lung Cancer, Nonsmall Cell</condition>
  <condition>Lung Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Pulmonary Nodule</arm_group_label>
    <description>Pulmonary nodule is suitable for elective bronchoscopy with a moderate to high risk of lung cancer based on clinical, demographic and radiologic information or with suspected metastatic disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ion Endoluminal System</intervention_name>
    <description>Robotic bronchoscopy with c-arm imaging.</description>
    <arm_group_label>Pulmonary Nodule</arm_group_label>
    <other_name>Cios 3D mobile spin system</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from pulmonary, medical oncology or thoracic surgery departments&#xD;
        at the Mayo Clinic Rochester.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject age 18 years and older&#xD;
&#xD;
          -  Subject is suitable for elective bronchoscopy&#xD;
&#xD;
          -  Subject with a moderate to high risk of lung cancer based on clinical, demographic and&#xD;
             radiologic information or with suspected metastatic disease&#xD;
&#xD;
          -  Solid or semi-solid pulmonary nodules of ≥ 1cm and ≤3.5 cm in largest dimension&#xD;
&#xD;
          -  Nodule is located in bronchial generation 4+ (i.e. beyond segmental bronchus)&#xD;
&#xD;
          -  Subject is a candidate for CT-guided needle biopsy&#xD;
&#xD;
          -  Subject is able to understand and adhere to study requirements&#xD;
&#xD;
          -  Subject is able to understand and adhere to study requirements and able to provide&#xD;
             informed consent&#xD;
&#xD;
          -  Subject is not legally incapacitated or in legal/court ordered institution&#xD;
&#xD;
          -  Subject has no dependency on the investigator or sponsor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of fitness or exercise capacity to undergo bronchoscopy under general anesthesia&#xD;
             as determined by physician prior to procedure&#xD;
&#xD;
          -  Acute myocardial infarction or unstable angina ≤ 6 weeks prior to study procedure&#xD;
&#xD;
          -  Clinically relevant partial trachea obstruction or obstruction of vena cava per&#xD;
             physician assessment&#xD;
&#xD;
          -  Acute respiratory failure, clinically significant hypoxemia, or high respiratory rate&#xD;
             (i.e. &gt; 30 breaths per minute) per physician assessment&#xD;
&#xD;
          -  Renal insufficiency that presents risk per physician's discretion or liver failure&#xD;
             (i.e. CHILD-PUGH Class C)&#xD;
&#xD;
          -  World Health Organization functional Class IV Pulmonary Hypertension or history of&#xD;
             clinically significant mPAP&#xD;
&#xD;
          -  Known or suspected pregnancy&#xD;
&#xD;
          -  Recent head injury (&lt;12 weeks pre-procedure) or subjects presenting with clinically&#xD;
             significant neurologic deficits&#xD;
&#xD;
          -  Unstable hemodynamic status (i.e. Dysrhythmia requiring intervention, altered mental&#xD;
             status/consciousness)&#xD;
&#xD;
          -  Inability to adequately oxygenate subject during procedure per physicians discretion&#xD;
             (i.e. unable to achieve S02 &gt; 88% or requiring &gt;4L of oxygen prior to procedure)&#xD;
&#xD;
          -  Subject with uncorrectable coagulopathy, bleeding or platelet disorders, history of&#xD;
             major bleeding with bronchoscopy&#xD;
&#xD;
          -  Subjects contraindicated for intubation or general anesthesia, or subjects with ASA ≥&#xD;
             5&#xD;
&#xD;
          -  Subjects taking antiplatelet (i.e. clopidogrel), anti-coagulant (i.e. heparin or&#xD;
             warfarin) or /platelet aggression inhibitors (i.e. Abciximac or Eptifibatide)&#xD;
             medications that cannot be stopped per standard practice, i.e. 5-7 days pre-procedure&#xD;
             or heparin that cannot be held according to standard practice (6-12 hours). Aspirin&#xD;
             not included.&#xD;
&#xD;
          -  Any severe or life-threatening comorbidity that could increase the risk of&#xD;
             bronchoscopic biopsy&#xD;
&#xD;
          -  Moderate-to-severe pulmonary fibrosis presenting procedural risk as assessed by&#xD;
             physician&#xD;
&#xD;
          -  Endobronchial lesion associated with lobar atelectasis&#xD;
&#xD;
          -  Known allergy, sensitivity or previous allergic reaction to ortho-phthalaldehyde (OPA)&#xD;
&#xD;
          -  Non-systemic treatment for lung cancer (i.e. SBRT) performed in the same lobe as the&#xD;
             target nodule(s)&#xD;
&#xD;
          -  Previous surgical intervention performed in the same lobe as the target nodule (s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janani Reisenauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bobbie Skaare</last_name>
    <phone>507-538-7168</phone>
    <email>Skaare.Bobbie@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Travis Fisher</last_name>
    <phone>507-538-7168</phone>
    <email>fisher.travis1@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie Skaare</last_name>
      <phone>507-538-7168</phone>
      <email>Skaare.Bobbie@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Travis Fisher</last_name>
      <phone>507-538-7168</phone>
      <email>fisher.travis1@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Janani Reisenauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Janani S. Reisenauer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
    <mesh_term>Multiple Pulmonary Nodules</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Solitary Pulmonary Nodule</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

